Activists warn trade pact will keep out generics (Update)

July 3, 2013 by Eileen Ng

A free trade pact being negotiated by the U.S. and 11 Asia-Pacific nations will impose aggressive intellectual property rules that could restrict access to affordable medicines in developing nations, health activists warned Wednesday.

The 12 countries will start an 18th round of talks in Malaysia on July 15 and hope to complete negotiations by October. Japan will join the Trans Pacific Partnership talks for the first time, alongside the United States, Australia, New Zealand, Canada, Brunei, Malaysia, Singapore, Vietnam, Peru, Chile and Mexico.

Fifa Rahman, from the Malaysian AIDS Council, said talks have been held in secret but leaked drafts of the agreement showed that Washington has proposed a tough intellectual property regime that will enhance patent and data protections for pharmaceutical companies and obstruct competition for cheaper generic versions of drugs.

This could further restrict access to affordable, life-saving medicines for millions of people, she said on the sidelines of an international AIDS conference.

"The TPP will be the icing on the cake for big pharmaceuticals. It will create a thicket of barriers around generic medicines and this will have a chilling effect on access to affordable medicines for many developing countries," said Leena Menghaney, from Doctors Without Borders.

Menghaney said the pact, billed as a model for future trade agreements worldwide, could set damaging precedents with serious implications for developing countries.

Provisions in the agreement will facilitate the practice of "evergreening," where pharmaceutical firms limit access to generic medicines by using various tactics to extend monopoly protection on drugs beyond the initial patent period, she said. She said companies would be able to seek multiple secondary patents on a single drug so that even when the original patent expires, the product is protected for years after.

Drug companies say that strong intellectual property protections are needed to foster investment in research to develop new and better drugs.

Once a drug's patent expires, generic manufacturers can legally produce it. They are able to make drugs at a fraction of the original manufacturer's cost because they don't carry out the expensive research and development.

Fauwaz Abdul Aziz of the Third World Network said the pact will further tip the balance toward commercial interests and away from public health. This could often be a matter of life and death in the developing world where people rarely have health insurance and pay for medicines out of pocket, he said.

Fifa said 80 percent of drugs used to treat HIV in developing countries are generics produced in India. But some countries such as Malaysia are already paying some of the highest prices for HIV drugs due to a poor procurement system and local patents, she said.

"If countries like Malaysia and Vietnam are part of an agreement that hinders the availability of affordable generics, people living with HIV who have exhausted all other treatment options will again face death," she said.

The groups urged member countries to renegotiate the provisions or withdraw from the talks to ensure public health interests are protected.

The 12 countries account for nearly 40 per cent of the global economy and about a third of world trade.

Explore further: Big Pharma battle threatens to delay Pacific trade pact

Related Stories

Big Pharma battle threatens to delay Pacific trade pact

March 10, 2013
A US-led Pacific free trade pact faces further delays as a row between Big Pharma and activists supporting access to generic drugs erupts ahead of an October deadline, officials say.

India rejects Bayer plea against cheap cancer drug (Update)

March 5, 2013
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive ...

India's top court to deliver Novartis judgment

March 31, 2013
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies that say they ...

Patents making new AIDS drugs expensive, MSF says

July 2, 2013
New potentially life-saving HIV drugs are "beyond reach" due to restrictive patents, Doctors Without Borders (MSF) said Tuesday, even though basic medication for the disease has become cheaper.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.